DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Merck's - 1 Kyle Holen - 1 Keytruda - 1 Stephane Bancel - 1 Bancel - 1
Top related locs:
Chicago U.S Moderna
Top related orgs:
Moderna - 1 Merck - 1 American Society of Clinical Oncology - 1 CNBC - 1 U.S . Food - 1 Drug Administration - 1 FDA - 1 American Cancer Society - 1

Search resuls for: "Kyle Holen"


2 mentions found


☆ Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
  + stars: | 2024-06-03 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
Moderna and Merck released more positive three-year data Monday on their experimental vaccine, given to patients with the most deadly form of skin cancer in combination with the therapy Keytruda. The vaccine together with Merck's Keytruda improved survival and showed long-lasting efficacy in a midstage study in patients with a deadly form of skin cancer. Melanoma is responsible for the large majority of skin cancer deaths, according to the American Cancer Society. Moderna is also conducting another phase three trial of the vaccine in patients with a type of lung cancer. This year, Merck and Moderna started a two-part mid- to late-stage trial on the vaccine and Keytruda in patients at an advanced stage of a common skin cancer.
Persons: Merck's, Kyle Holen, Keytruda, Stephane Bancel, Bancel Organizations: Moderna, Merck, American Society of Clinical Oncology, CNBC, U.S . Food, Drug Administration, FDA, American Cancer Society Locations: Chicago, U.S, Moderna
☆ Moderna shares fall despite promising data from cancer vaccine trial
  + stars: | 2023-04-17 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Shares of Moderna fell Monday as Wall Street chewed over new trial results on the personalized cancer vaccine it is developing with Merck . Those results, presented at an American Association for Cancer Research meeting in Florida, add to the initial results on the treatment combination released in December. Analysts from SVB Securities said the results suggest the personalized cancer vaccine shows promise. Wells Fargo analyst Mohit Bansal also said he's expressing "cautious optimism" about the treatment combination. In a Sunday note, Bansal pointed to "trial imbalances" that potentially produced more favorable results for the personalized cancer vaccine.
0 next >>
Total: 2